Compare Tidewater Inc (TDW) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tidewater Inc vs Viatris Inc — how do they compare? Tidewater Inc trades at $85.42 (market cap $4.21B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 4.8× Tidewater Inc's market cap, and Viatris Inc pays a 2.75% dividend while Tidewater Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tidewater Inc for 26 Days and Viatris Inc for 57 Days on average.
| TDW | VTRS | |
|---|---|---|
Market Cap | $4.21B | $20.03B |
Volume | 590,005 | 14,109,977 |
Sector | Energy | Health |
52-Week High | $100.61 | $18.27 |
52-Week Low | $47.29 | $9.74 |
Typical Hold Time | 26 Days | 57 Days |
Enterprise Value | $4.25B | $32.15B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tidewater (TDW) trades at $85.42, up 2.42% with bullish technical indicators and strong institutional interest. The company maintains solid profitability with 18.34% net margin and 19.49% ROE, though recent quarterly earnings have missed expectations. Recent acquisition of Wilson Sons Ultratug expands offshore services capabilities, while BlackRock's $503 million investment signals confidence in long-term prospects.
TDW presents a mixed outlook with analyst consensus target of $105.50 offering 23% upside potential, but faces execution risks from recent earnings misses and Middle East operational costs. The stock's valuation at 17.18 P/E appears reasonable given growth prospects, though investors should monitor quarterly performance consistency and integration of recent acquisitions.
Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical signal from moving averages and oversold short-term RSI. The company reported three consecutive quarterly earnings beats in 2026, with Q2 EPS of $0.69 beating estimates by 14.8%. Revenue for 2025 was $14.3B, though net income was negative $3.51B, reflecting margin pressure. Positive news includes a new drug approval in Japan and recognition as a top employer.
The outlook is mixed: strong cash flow generation and deleveraging support shareholder returns via dividends and buybacks, but profitability challenges and high debt levels pose risks. Analyst consensus is a 'Buy' with a $22.17 price target, implying 27% upside. Investment appeal hinges on execution of pipeline growth and margin improvement amid competitive and pricing pressures in the generics market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
